Nervenheilkunde 2012; 31(10): 733-757
DOI: 10.1055/s-0038-1628187
Expertenempfehlung
Schattauer GmbH

Kopf- und Gesichtsschmerzen im Alter

Epidemiologie, Klinik und Therapie Expertenempfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft in Zusammenarbeit mit der Österreichischen Kopfschmerzgesellschaft und der Schweizerischen KopfwehgesellschaftHeadache and facial pain in the elderlyEpidemiology, clinic and therapy
A. Straube
1   Neurologische Klinik der Universität München
,
B. Hinz
2   Institut für Toxikologie und Pharmakologie, Universität Rostock
,
P. Kropp
3   Institut für Medizinische Psychologie und Medizinische Soziologie, Universität Rostock
,
S. Förderreuther
1   Neurologische Klinik der Universität München
,
C. Lampl
4   Neurologie der Barmherzigen Brüder, Linz, Österreich
,
P. Sandor
5   Kantonsspital Baden, Baden, Schweiz
,
A. May
6   Institut für systemische Neuroforschung, Uniklinik Hamburg Eppendorf
,
G. Haag
7   Michael Balint Klinik, Königsfeld
› Author Affiliations
Further Information

Publication History

Eingegangen am: 24 April 2012

angenommen am: 25 April 2012

Publication Date:
23 January 2018 (online)

Zusammenfassung

Die sozio-demografische Entwicklung bedingt, dass sich immer häufiger ältere und alte Menschen mit Kopfschmerzen klinisch vorstellen. Diese Leitlinie soll ein erster Versuch sein, die Literatur zu Kopfschmerzen und Gesichtsschmerzen bei dieser Patientengruppe zusammenzufassen und spezifische Therapie-Empfehlungen zu geben. Dabei zeigt sich, dass die Alters-gruppe der über 65-Jährigen in fast allen Therapiestudien nicht berücksichtigt wird und die übrigen Studien meist diese Altersgruppe nicht betrachten. Wenig untersucht ist der Wandel der Symptome bei primären Kopfschmerzen in Abhängigkeit vom Alter. Generell treten bei Migräne vegetative Symptome seltener auf und Kopfschmerzen werden häufiger als drückend beschrieben. Der idiopathische schlafgebundene Kopfschmerz, die Arteriitis cranialis, die post-zosterische Neuralgie und die klassische Trigeminusneuralgie sind Erkrankungen, die ausschließlich bzw. vorwiegend im höheren Alter auftreten. Therapiestudien mit älteren Patienten sind nicht publiziert, generell gilt die Emp-fehlung, Leber- und Nierenfunktion zu beach-ten, niedrig dosiert zu beginnen und die Dosis langsam bis zur Wirksamkeit zu steigern.

Summary

The part of elderly people is strongly increasing in all western countries. This is the reason for that more elderly patients with headaches are seen in the health system. The present guideline tries to screen the available literature about headaches in the elderly and to develop therapeutic recommendations. Generally there is only a small number of paper which deal with this specific topic and there are nearly no studies about the headache therapy in patients older than 65 years. There is some evidence that the symptoms of primary headaches change with age and that the vegetative symptoms decrease and the headaches become more prominent. There are also some headache and facial pain syndromes which mostly develop in patients older than 50 years, e.g. hypnic headache, giant arthritis, zoster neuralgia and trigeminal neuralgia.

 
  • Literatur

  • 1 Bräuninger M. et al. Gesundheitsentwicklung in Deutschland bis 2037 – Eine volkswirtschaftliche Kostensimulation. Hamburg: Hamburgisches Weltwirtschaftsinstitut HWWI; 2007
  • 2 Basler HD. Besonderheiten der Diagnostik und Therapie des Schmerzes im Alter. Verhaltenstherapie & Verhaltensmodifikation 2007; 28 (Suppl. 03) 398-406.
  • 3 Jones GT, Macfarnale GA. Epidemiology of pain in older persons. In: SJ Gibson, DK Weiner (eds.).. Pain in older persons. Seattle: IASP Press; 2005: 3-24.
  • 4 Warden V, Hurley A, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) Scale. J Am Med Dir Assoc 2003; 4: 9-15.
  • 5 Basler HD. et al. Beurteilung von Schmerz bei Demenz (BESD) – Untersuchung zur Validität eines Verfahrens zur Beobachtung des Schmerzverhaltens. Schmerz 2006; 20: 519-26.
  • 6 Bollschweiler E. Leitlinien Entwicklung – Nationale und klinikinterne Leitlinien: Definition und Problemlage. In: Lauterbach KW, Schrappe M. (Hrsg.). Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Stuttgart: Schattauer; 2001: 457-63.
  • 7 Lüring C, Koester B, Grifka J. Gibt es Evidenz in der evidenzbasierten Medizin? Ein Vergleich gängiger Klassierungssysteme und kritische Auseinandersetzung. Z Orthop 2006; 144: 563-8.
  • 8 Prencipe M. et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001; 70: 377-81.
  • 9 Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982–1985. Arthritis Rheum 1987; 30: 294-9.
  • 10 Evers S, Goadsby PJ. Hypnic headache – a literature review on clinical features, pathophysiology, treatment. Neurology 2003; 60: 905-9.
  • 11 Pfaffenrath V. et al. Regional variations in the prevalence of migraine and tension-type headache applying the new IHS criteria: the German DMKG Headache Study. Cephalalgia 2009; 29 (Suppl. 01) 48-57.
  • 12 Olesen J. et al. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 (Suppl. 01) 1-160.
  • 13 Schwaiger J. et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55–94 years (Bruneck Study). Cephalalgia 2009; 29 (Suppl. 02) 179-87.
  • 14 Victor TW. et al. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010; 30 (Suppl. 09) 1065-72.
  • 15 Mattsson P. et al. The prevalence of migraine in women aged 40–74 years: a population-based study. Cephalalgia 2000; 20 (Suppl. 10) 893-9.
  • 16 Bigal ME, Libermann JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology 2006; 67: 246-51.
  • 17 Martins KM, Bordini CA, Bigal ME, Speciali JG. Migraine in the elderly: a comparision with migraine in young adults. Headache 2006; 46: 312-6.
  • 18 Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992; 12 (Suppl. 04) 221-8.
  • 19 Haan J, Hollander J, Ferrari MD. Migraine in the elderly: a review. Cephalalgia 2007; 27 (Suppl. 02) 97-106.
  • 20 Wöber-Bingöl C. et al. Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia 2004; 24 (Suppl. 01) 12-7.
  • 21 Kelman L. Migraine changes with age: Impact on migraine classification. Headache 2006; 46: 1161-71.
  • 22 Wöber C. et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalagia 2007; 27: 304-14.
  • 23 Meyer JS. et al. Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia 1998; 18 (Suppl. 04) 202-8.
  • 24 Kurth T. et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64 (Suppl. 06) 1020-6.
  • 25 Evers S. et al. Akuttherapie und Prophylaxe der Migräne. Leitlinie der Deutschen Migräne- und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008; 27: 933-49.
  • 26 Straube A. et al. Therapie primärer chronischer Kopfschmerzen. Chronische Migräne, chronischer Kopfschmerz vom Spannungstyp und andere chronische tägliche Kopfschmerzen. Schmerz 2008; 22: 531-43.
  • 27 Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24 (Suppl. 08) 1457-69.
  • 28 Sudano I. et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010; 122 (Suppl. 18) 1789-96.
  • 29 MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361 9357 573-4.
  • 30 Tepper SJ. Serotonin Syndrome: SSRIs, SNRIs, Triptans, and Current Clinical Practice. Headache. 2012 Jan 6. doi: 10.1111/j.15264610.2011.02076.x.
  • 31 Maas HJ, Danhof M, Della Pasqua OE. Analysis of the relationship between age and treatment response in migraine. Cephalalgia 2009; 29 (Suppl. 07) 772-80.
  • 32 Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging 2010; 5: 89-99.
  • 33 Stovner LJ. et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalagia 2007; 27: 193-210.
  • 34 Kaniecki RG. Tension-type headache in the elderly. Curr Treat Options Neurol 2007; 9: 31-7.
  • 35 Russel MB. et al. Tension-type headache in adolescents and adults: a population based study of 33, 764 Twins. Eur J Epidem 2006; 21: 153-60.
  • 36 Fuh JL. et al. A 13-year long-term outcome study of elderly with chronic daily headache. Cephalalgia 2008; 28: 1017-22.
  • 37 Buchgreiz L, Lyngberg AC, Bendtsen L, Jensen R. Increased prevalence of tension-type headache over a 12-year period is related to increased pain sensitivity. A population study. Cephalagia 2007; 27: 145-52.
  • 38 Kaniecki RG. Tension-type headache in the elderly. Curr Pain Headache Rep 2006; 10: 448-53.
  • 39 Taylor D. Venlafaxine and cardiovascular toxicity. BMJ 2010; 340: c411.
  • 40 Ekbom K, Svensson DA, Pedersen NL, Waldenlind E. Lifetime prevalence and concordance risk of cluster headache in the Swedish twin population. Neurology 2006; 67: 798-803.
  • 41 Fischera M, Anneken K, Evers S. Old age of onset in cluster-headache patients. Headache 2005; 45: 615-6.
  • 42 May A. et al. Treatment and prophylaxis for cluster headaches and other trigeminal autonomic headaches. Revised recommendations of the German Migraine and Headache Society. Schmerz 2005; 19 (Suppl. 03) 225-41.
  • 43 Bigal ME. et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache 2010; 50 (Suppl. 02) 256-63.
  • 44 Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache 2009; 49 (Suppl. 01) 117-25.
  • 45 Ashkenazi A, Schwedt T. Cluster headache – acute and prophylactic therapy. Headache 2011; 51 (Suppl. 02) 272-86.
  • 46 Steiner TJ. et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 1997; 17 (Suppl. 06) 673-5.
  • 47 Price W, Shalley J. Lithium-verapamil toxicity in the elderly. Journal of the American Geriatrics Society 1987; 35 (Suppl. 02) 177-8.
  • 48 Donnet A, Lantéri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia 2009; 29 (Suppl. 09) 928-34.
  • 49 Gil-Gouveia R, Goadsby PJ. Secondary hypnic headache“. J Neurol 2007; 254: 646-54.
  • 50 Evers S, Frese A, May A, Sixt G, Straube A. Therapie seltener idiopathischer Kopfschmerzerkrankungen. Empfehlungen der DMKG. Nervenheilkunde 2005; 24: 217-26.
  • 51 Truelsen T. et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13 (Suppl. 06) 581-98.
  • 52 Arboix A. et al. Headache in acute cerebrovascular disease: a prospective clinical study in 240 patients. Cephalagia 1994; 14: 37-40.
  • 53 Diener HC, Katsarava Z, Weimar C. Headache associated with ischemic cerebrovascular disease. Rev Neurol (Paris) 2008; 164 (Suppl. 10) 819-24.
  • 54 Naganuma M. et al. Clinical characteristics of subarachnoid hemorrhage with or without headache. J Stroke Cerebrovasc Dis 2008; 17 (Suppl. 06) 334-9.
  • 55 Agostoni E. Headache in cerebral venous thrombosis. Neurol Sci 2004; 25 (Suppl. 03) S206-10.
  • 56 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6 (Suppl. 02) 162-70.
  • 57 Arboix A. et al. Stroke-related headache: a clinical study in lacunar infarction. Headache 2005; 45: 1345-52.
  • 58 Mitsias PD. et al. Factors determining headache at onset of acute ischemic stroke. Cephalalgia 2006; 26 (Suppl. 02) 150-7.
  • 59 Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol 2010; 9 (Suppl. 03) 309-17.
  • 60 Rosenberg JH, Silberstein SD. The headache of SAH responds to sumatriptan. Headache 2005; 45 (Suppl. 05) 597-8.
  • 61 Ferro JM, Melo TP, Guerreiro M. Headache in intra-cerebral hemorrhage survivors. Neurology 1998; 50: 203-7.
  • 62 Damak M, Crassard I, Wolff V, Bousser MG. Isolated lateral sinus thrombosis: a series of 62 patients. Stroke 2009; 40 (Suppl. 02) 476-81.
  • 63 Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982–1985. Arthritis Rheum 1987; 30: 294-99.
  • 64 Ward TN, Levin M. Headache in giant cell arteritis and other arteritides. Neurol Sci 2005; 26: 134-7.
  • 65 Eberhardt RT, Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev 2007; 15: 55-61.
  • 66 Lipton RB, D.P Newman LC, Solomon S. Headaches in the elderly. J Pain Symptom Manage 1993; 8: 87-97.
  • 67 Goffaux P, Fortin D. Brain tumor headaches: from bedside to bench. Neurosurgery 2010; 67 (Suppl. 02) 459-66.
  • 68 Schankin CJ. et al. Characteristics of brain tumour-associated headache. Cephalalgia 2007; 27 (Suppl. 08) 904-11.
  • 69 Levy MJ. et al. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005; 128 Pt 8 1921-30.
  • 70 Roberts RG, Redman JW. Indomethacin – a review of its role in the management of traumatic brain injury. Crit Care Resusc 2002; 4 (Suppl. 04) 271-80.
  • 71 Schwabe U, Paffrath D. Arzneiverordungs-Report. Heidelberg: Springer; 1997
  • 72 Straube A. et al. Prevalence of chronic migraine and medication overuse headache in Germany-the German DMKG headache study. Cephalalgia 2010; 30: 207-13.
  • 73 Jensen R, Bendtsen L. Medication overuse headache in Scandinavia. Cephalalgia 2008; 28 (Suppl. 11) 1237-9.
  • 74 Toth C. Medications and substances as a cause of headache: a systemic review of the literature. Clin Neuropharacol 2003; 26: 122-36.
  • 75 Pöllmann W. et al. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59 (Suppl. 04) 636-9.
  • 76 Allais G. et al. Headache induced by the use of combined oral contraceptives. Neurol Sci 2009; 30 Suppl 1: S15-7.
  • 77 Rogers PJ. et al. Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. Psychopharmacology (Berl) 2005; 179 (Suppl. 04) 742-52.
  • 78 Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am Heart J 1982; (2 Pt 2): 473-8.
  • 79 Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61: 160-4.
  • 80 Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalagia 2006; 26: 1192-8.
  • 81 Straube A. et al. Therapie primärer chronischer Kopfschmerzen: Chronische Migräne, chronische Kopfschmerzen vom Spannungstyp und andere chronische tägliche Kopfschmerzen. Nervenheilkunde 2007; 3: 186-99.
  • 82 Sjaastad O, Fredriksen TA. Cervicogenic headache: criteria, classification and epidemiology. Clin Exp Rheumatol 2000; 18 2 Suppl 19 S3-6.
  • 83 Sjaastad O, Bakketeig LS. Prevalence of cervicogenic headache: Vågå study of headache epidemiology. Acta Neurol Scand 2008; 117 (Suppl. 03) 173-80.
  • 84 69 Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. Clin Exp Rheumatol 2000; (2 Suppl 19): S59-64.
  • 85 Uthaikhup S, Sterling M, Jull G. Cervical musculoskeletal impairment is common in elders with headache. Man Ther 2009; 14 (Suppl. 06) 636-41.
  • 86 Nordin M. et al. Assessment of neck pain and its associated disorders: results of the Bone and Joint Decade 2000–2010 Task Force on Neck Pain and Its Associated Disorders. J Manipulative Physiol Ther 2009; 32 (Suppl. 02) S117-40.
  • 87 Iansek R, Heywood J, Karnaghan J, Balla JI. Cervical spondylosis and headaches. Clin Exp Neurol 1987; 23: 175-8.
  • 88 Varenna M. et al. Demographic and clinical features related to a symptomatic onset of Paget’s disease of bone. J Rheumatol 2010; 37 (Suppl. 01) 155-60.
  • 89 Ylinen J. et al. Effect of neck exercises on cervicogenic headache: a randomized controlled trial. J Rehabil Med 2010; 42 (Suppl. 04) 344-9.
  • 90 Ashkenazi A. et al. Interventional Procedures Special Interest Section of the American Peripheral nerve blocks and trigger point injections in headache management – a systematic review and suggestions for future research. Headache 2010; 50 (Suppl. 06) 943-52.
  • 91 Provini F, Vetrugno R, Lugaresi E, Montagna P. Sleep-related breathing disorders and headache. Neurol Sci 2006; 27: 149-52.
  • 92 Wittchen HU. et al. Hypertension, diabetes mellitus and comorbidity in primary care. Fortschr Med Orig 2003; 27: 19-27.
  • 93 Cortelli P. et al. Headache and hypertension. Neurol Sci 2004; 25 Suppl 3: S132-4.
  • 94 Liman T, Siebert E, Endres M. Kopfschmerz und Blutdruck. Nervenarzt 2010; 81: 963-72.
  • 95 Bulpitt CJ, Dollery CT, Carne S. Change in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J 1976; 38: 121-8.
  • 96 Rasmussen BK, Olesen J. Symptomatic and non-symptomatic headaches in a general population. Neurology 1992; 42: 1225-31.
  • 97 Muiesan ML. et al. Prevalence and relationship with office or ambulatory blood pressure in a general population sample (the Vobarno Study). Blood Press 2006; 15: 14-9.
  • 98 Tronvik E. et al. High pulse pressure protects against headache: prospective and cross-sectional data (HUNT study). Neurology 2008; 70 (Suppl. 16) 1329-6.
  • 99 Bigal ME. et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010; 74 (Suppl. 08) 628-35.
  • 100 Antoniazzi AL. et al. Headache associated with dialysis: the International Headache Society criteria revisted. Cephalagia 2003; 23: 146-9.
  • 101 Antoniazzi AL. et al. Headache and hemodialysis: a prospective study. Headache 2003; 43: 146-9.
  • 102 Weisel M. Possible consequences of subclinical hypothyroidism. Acta Med Austriaca 2003; 30: 93-7.
  • 103 Moreau T. et al. Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Cephalagia 1998; 18: 687-9.
  • 104 Wei JH, Wang HF. Cardiac cephalalgia: case reports and review. Cephalalgia 2008; 28 (Suppl. 08) 892-6.
  • 105 Provini F. et al. Sleep-related breathing disorders and headache. Neurol Sci 2006; 27: 149-52.
  • 106 Goksan B. et al. Morning headache in sleep apnoea: clinical and polysomnographic evaluation and response to nasal continuous positive airway pressure. Cephalalgia 2009; 29 (Suppl. 06) 635-41.
  • 107 Alberti A. et al. Headache characteristics in obstructive sleep apnea syndrom and insomnia. Acta Neu-rol Scand 2005; 111: 309-16.
  • 108 Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation 2005; 112 (Suppl. 15) 2301-6.
  • 109 Straube A. Diagnostik und Therapie von Gesichtsschmerzen. Angewandte Schmerztherapie und Palliativmedizin 2009; 4: 40-6.
  • 110 Paulus W. et al. Therapie und Prophylaxe von Gesichtsneuralgien und anderen Formen von Gesichtsschmerzen. Schmerz 2003; 17 (Suppl. 01) 74-91.
  • 111 Batochi AP. et al. Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases. J Neurol 1997; 244: 639-45.
  • 112 Gottesman MH. et al. Cardiac arrest caused by trigeminal neuralgia. Headache 1996; 36 (Suppl. 06) 392-4.
  • 113 Cruccu G. et al. Small-fiber dysfunction in trigeminal neuralgia: carbamazepine effect on laser-evoked potentials. Neurology 2001; 56 (Suppl. 12) 1722-6.
  • 114 Kress B. et al. MRI volumetry for the preoperative diagnosis of trigeminal neuralgia. Eur Radiol 2005; 15 (Suppl. 07) 1344-8.
  • 115 Sommer C. Therapie neuropathischer Schmerzsyndrome. Bremen: Uni Verlag; 2006
  • 116 Truini A. et al. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study. Pain 2008; 140 (Suppl. 03) 405-10.
  • 117 Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002; 25: 477-91.
  • 118 Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. J Pain Symptom Manage 2001; 21 (Suppl. 06) 506-10.
  • 119 Cruccu G. et al. American Academy of Neurology Society; European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neural-gia management. Eur J Neurol 2008; 15 (Suppl. 10) 1013-28.
  • 120 Bennetto L, Patel NK, Fuller G. Trigeminal neural-gia and its management. BMJ 2007; 27: 201-5.
  • 121 Elsner F. et al. Opoidwirksamkeit am Ganglion cervicale superius bei neuropathischen Schmerzen im Kopf-und Gesichtsbereich. Schmerz 2006; 20 (Suppl. 04) 268-72.
  • 122 Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9 (Suppl. 08) 807-19.
  • 123 Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27 (Suppl. 02) 159-76.
  • 124 Oxman MN. Vaccination to prevent herpes zoster and postherpetic neuroalgia. Hum Vaccin 2007; 3: 64-8.
  • 125 Adams EN, Parnapy S, Bautista P. Herpes zoster and vaccination: a clinical review. Am J Health Syst Pharm 2010; 67 (Suppl. 09) 724-7.
  • 126 Lake AE, Rains JC, Penzien DB, Lipchik GL. Headache and psychiatric comorbidity: Historical Context, clinical implications, and research relevance. Headache 2005; 45: 493-506.
  • 127 Dodick DW. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia 2009; 29 Suppl 3: 7-14.
  • 128 Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000; 40: 818-23.
  • 129 Wang S. et al. Comorbidity of headaches and depression in the elderly. Pain 1999; 82: 239-43.
  • 130 Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol 2009; 5: 363-89.
  • 131 Snowdon J. Is depression more prevalent in old age?. Aust N Z J Psychiatry 2001; 35: 782-7.
  • 132 Allaz AF. Psychological components of chronic pain in the elderly. Psychologie & Neuropsychiatrie du Viellissement 2006; 4: 103-8.
  • 133 Jelicic M, Kepmen G, Passchier J. Psychological well-being in older adults suffering from chronic headache. Headache 1998; 38: 292-4.
  • 134 Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serontonin re-uptake inhibitors (SSRI) for preventing migraine and tension-type headache. Cochrane Database Syst Rev 2005; 20: 1-50.
  • 135 Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry 2008; 69 (Suppl. 09) 1449-54.
  • 136 Ozyalcin SN. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (Suppl. 02) 144-52.
  • 137 van Melle JP, de Jonge P. Beta-blocker use and the development of depression. Am J Cardiol 2009; 103 (Suppl. 09) 1331-2.
  • 138 Hinz B. et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J 2007; 21 (Suppl. 10) 2343-51.
  • 139 Weinberger I, Joshua H, Friedmann J, Rahamim S, Agmon J. Inhibition of ADP-induced platelet aggregation by dipyrone in patients with acute myocardial infarction. Thromb Haemost 1979; 42 (Suppl. 02) 752-6.
  • 140 Werner U. et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003; 74 (Suppl. 02) 130-7.